NCT05459220Unknown3 期
A Phase Ⅲ, Randomized, Double-blind, Placebo-controlled Study of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 357
- 主要终点
- Summed Pain Intensity Difference From 0-24 Hours (SPID0-24)
研究概览
简要总结
The study is being conducted to evaluate the efficacy and safety of SHR0410 injection for the treatment of pain after laparoscopic surgery
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent
- •Subjects requiring elective general anesthesia endoscopic surgery of the lower abdominal
- •Male or female
- •Meet the body mass index standard
- •Conform to the ASA Physical Status Classification
排除标准
- •Subjects with a history of difficult airway
- •Subjects with a history of mental illness
- •Subjects with a history of cognitive impairment epilepsy
- •Subjects with a history of myocardial infarction or unstable angina pectoris
- •Subjects with atrioventricular block or cardiac insufficiency
- •Subjects with a history of ischemic stroke or transient ischemic attack
- •Subjects with poor blood pressure control after medication
- •Subject with a history of substance abuse and drug abuse
- •Abnormal values in liver function
- •Allergic to drugs that may be used during the study
- •Pregnant or nursing women
- •No birth control during the specified period of time
- •Participated in clinical trials of other drugs (received experimental drugs)
- •The investigators determined that other conditions were inappropriate for participation in this clinical trial
研究组 & 干预措施
Treatment group A
Experimental
SHR0410 Injection（Low Dose）
干预措施: SHR0410 Injection (Drug)
Treatment group B
Experimental
SHR0410 Injection（High Dose）
干预措施: SHR0410 Injection (Drug)
Treatment group C
Placebo Comparator
Placebo for SHR0410 Injection.
干预措施: Placebo (Drug)
结局指标
主要结局
Summed Pain Intensity Difference From 0-24 Hours (SPID0-24)
时间窗: 0 to 24 hours
Pain intensity will be evaluated using an 11-point (0-10) numeric rating scale (NRS), with higher numbers indicating a higher pain intensity.
次要结局
- Estimated Time From The Start Of The Infusion Of Study Drug To The First NRS reaching 3 or less(0 to 24 hours)
- Total Pain Relief Within The First 2 Hours、4 Hours、6 Hours、12 Hours、18 Hours、24 Hours(0 to 2 hours、0 to 4 hours、0 to 6 hours、0 to 12 hours、0 to 18 hours、0 to 24 hours)
- Total consumption of remedial analgesics from 0 to 24 hours(24-hours)
- Participant' Satisfaction Score For Analgesia Treatment(24-hours)
- Investigator Satisfaction Score For Analgesia Treatment(24-hours)
- Numbers of Participants With Abnormal Vital Signs(Day 3 or Day 4)
- Numbers of Participants With Abnormal Laboratory Values(Day 3 or Day 4)
- Summed Pain Intensity Difference Within The First 2 Hours、4 Hours、6 Hours、12 Hours、18 Hours (SPID2、SPID4、SPID6、 SPID12、SPID18)(0 to 2 hours、0 to 4 hours、0 to 6 hours、0 to 12 hours、0 to 18 hours)
研究者
相似试验
已完成
3 期
A Trial of SHR0410 Injection for the Treatment of Pain After Endoscopic Surgery of the Lower AbdominalPainNCT04852003Jiangsu HengRui Medicine Co., Ltd.228
终止
2 期
A Trial of SHR0410 Injection in Postsurgical Pain ManagementPostsurgical PainNCT05394402Jiangsu HengRui Medicine Co., Ltd.31
Unknown
1 期
A Study of SHR0410 in Hemodialysis Patients With PruritusPruritusNCT04317209Jiangsu HengRui Medicine Co., Ltd.54
招募中
2 期
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）Eosinophilic Granulomatosis With PolyangiitisNCT05979051Guangdong Hengrui Pharmaceutical Co., Ltd166
已完成
1 期
A Study of SHR4010 in Patients With HemodialysisPruritusNCT04099927Jiangsu HengRui Medicine Co., Ltd.12